Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
Children with three copies of SMN2 treated presymptomatically achieved age-appropriate milestones, including standing and walking;…